Gibberella Zeae
Generic Name: gibberella zeae
Brand Names:
Gibberella Pulicaris
Dosage form: INJECTION, SOLUTION. Route: PERCUTANEOUS, SUBCUTANEOUS. Active ingredients: GIBBERELLA ZEAE (.05 g/mL). Category: BLA.
Overview
Dosage form: INJECTION, SOLUTION. Route: PERCUTANEOUS, SUBCUTANEOUS. Active ingredients: GIBBERELLA ZEAE (.05 g/mL). Category: BLA.
Dosage
Available as injection, solution for percutaneous, subcutaneous use.
Related Medications
Gel Fluoride Toothpaste
gel fluoride toothpaste
Anticavity
Iris Versicolor, Solidago Virgaurea, Aconitum Napellus, Agaricus Muscarius, Allium Cepa, Allium Sativum, Antimonium Crudum, Arsenicum Album, Baptisia Tinctoria, Bovista, Caffeinum, Capsicum Annuum, Cinchona Officinalis, Cinnamomum, Coccus Cacti, Cynara Scolymus, Fragaria Vesca, Gelsemium Sempervirens, Histaminum Hydrochloricum, Ipecacuanha, Jequerity, Juglans Regia, Lachesis Mutus, Ledum Palustre, Lycopodium Clavatum, Mentha Piperita, Natrum Muriaticum, Nux Moschata,
iris versicolor, solidago virgaurea, aconitum napellus, agaricus muscarius, allium cepa, allium sativum, antimonium crudum, arsenicum album, baptisia tinctoria, bovista, caffeinum, capsicum annuum, cinchona officinalis, cinnamomum, coccus cacti, cynara scolymus, fragaria vesca, gelsemium sempervirens, histaminum hydrochloricum, ipecacuanha, jequerity, juglans regia, lachesis mutus, ledum palustre, lycopodium clavatum, mentha piperita, natrum muriaticum, nux moschata,
Vitamin C [EPC]
OTC - PURPOSE SECTION Formulated for associated symtoms such as itching, swelling, headaches, indigestion, vomiting and cramping.
Anifrolumab-fnia
anifrolumab-fnia
Type I Interferon Receptor Antagonist [EPC]
11 DESCRIPTION Anifrolumab-fnia is a type I interferon (IFN) receptor antagonist, immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that is produced in mouse myeloma cells (NS0) by recombinant DNA technology. The molecular weight is approximately 148 kDa. SAPHNELO (anifrolumab-fnia) injection is a sterile, preservative‑free, clear to opalescent, colorless to slightly yellow, solution for intravenous use. SAPHNELO contains anifrolumab-fnia at a concentration of 150 mg/mL in a single-dose vial.
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.